Drug – bio-affecting and body treating compositions – Enzyme or coenzyme containing – Transferases
Patent
1995-05-01
1996-10-22
Wityshyn, Michael G.
Drug, bio-affecting and body treating compositions
Enzyme or coenzyme containing
Transferases
435232, A61K 3851
Patent
active
055674178
ABSTRACT:
Pharmaceutical compositions for delivering an effective dose to a desired site of a heparinase. These compositions are based on the discovery that heparinase alone can inhibit angiogenesis. The effective dosage is dependent not only on the heparinase, but also on the method and means of delivery, which can be localized or systemic. For example, in some applications, as in the treatment of psoriasis or diabetic retinopathy, the inhibitor is delivered in a topical ophthalmic carrier. In other applications, as in the treatment of solid tumors, the inhibitor is delivered by means of a biodegradable, polymeric implant.
REFERENCES:
Vlodavsky et al., PNAS USA 84: 2292-2296 (Apr. 1987).
Folkman et al., Am J. Pathol. 130(2): 393-400 (Feb. 1988).
Bashkin et al., Biochemistry 28: 1737-1743 (1989).
Nakajima et al., J. of Biol. Chem 259(4): 2283-2290 (1984).
Auerback, et al., J. Microvasc. Res., 29:401-411 (1985).
Ausprunk, D. H., et al., "Migration and Proliferation of Endothelial Cells in Preformed and Newly Formed Blood Vessels During Tumor Angiogenesis", J. Microvasc. Res., 14:153-65 (1977).
Baird, A., et al., N. Biochem. Biophy. Res. Commun., 142:428-435 (1987).
Bohmer, L. H., et al., "Purification and Characterization of a Novel Heparinase", J. Biol. Chem., 265(23):13609-13617 (1990).
Casu, B., "Structure and Biological Activity of Heparin", Adv. Carbohydr. Chem. Biochem., 43:51-134 (1985).
D'Amore, et al., "Endothelial Cell Mitogens Derived from Retina and Hypothalamus: Biochemical and Biological Similarities", J. Cell Biol., 99:1545-1549 (1984).
Folkman, J. et al., "Minireview-Angiogenesis", J. Biol. Chem., 267(16):10931-10934 (1992).
Folkman, J., et al., "A Heparin-Binding Angiogenic Protein-Basic Fibroblast Growth Factor-Is Stored Within Basement Membrane", Am. J. Pathol., 130:393-400 (1988).
Folkman, J., et al., "Angiogenesis Inhibition and Tumor Regression Caused by Heparin or a Heparin Fragment in the Presence of Cortisone", Science, 221:719-725 (1983).
Folkman, J., et al., "Angiogenic Factors", M. Science, 235:442-447 (1987).
Folkman, J., "Tumor Angiogenesis", Advances in Cancer Research, Academic Press, Inc., New York, 43:175-203 (1985).
Folkman, J., et al., "Control of Angiogenesis With Synthetic Heparin Substitutes", Science, 243:1490-1493 (1989).
Galliher, P. M., et al., "Regulation of Heparinase Synthesis in Flavobacterium Heparinum ", Eur. J. Appl. Micorbiol. Biotechnol. 15:252-257 (1982).
Galliher, P. M. et al., "Heparinase Production by Flavobacterium Heparinum ", Appl. Environ. Microbiol., 41(2):360-365 (1981).
Gitay-Goren, et al., "The Binding of Vascular Endothelial Growth Factor to Its Receptors is Dependent on Cell Surface-associated Herapin-like Molecules", J. Biol. Chem., 267(9):6093-6098 (1992).
Gospodarowicz, D., et al., "Heparin Protects Basic and Acidic FGF From Inactivation", J. Cell Physiol., 128:475-484 (1986).
Jacobson, I., et al., "Biosynthesis of Heparin (Concerted Action of Late Polymer-modification Reactions)", J. Biol. Chem. 255:5094-5100 (1980).
Kiefer, M. C., et al., "Ligand-affinity Cloning and Structure of a Cell Surface Heparan Sulfate Proteoglycan That Binds Basic Fibroblast Growth Factor", Proc. Natl. Acad. Sci. USA, 87:6985-6989 (1990).
Kurokawa, M., et al., "Neutralizing antibodies inhibit. . . ," J. Biol. Chem., vol. 264, No. 13, pp. 7686-7691 (May 5, 1989).
Klagsbrun, M., et al., "A Dual Receptor System Is Required For Basic Fibroblast Growth Factor Activity", Cell, 67:229-231 (1991).
Lindahl, U., et al., "Biosynthesis of Heparin", Trends Biochem. Sci., 11:221-225 (1986).
Lindahl, U., et al., "Biosynthesis of Heparin and Heparan Sulfate", The Biology of Proteoglycans, Academic Press, Inc., 59-104 (1987).
Lindblom, A., et al., "Domain Structure of Endothelial Heparan Sulphate", Biochem J., 279:821-829 (1991).
Lindhardt, R. J., et al., "Search for the herapin Antithrombin III-binding Site Precursor", J. Biol. Chem., 267:2380-2387 (1992).
Lindhardt, R. J., "Heparin: An Important Drug Enters Its Seventh Decade", Chemistry & Industry, 45-50 (1991).
Lobb, R. R., "Thrombin Inactivates Acidic Fibroblast Growth Factor but Not Basic Fibroblast Growth Factor", Biochem., 27:2572-2578 (1988).
Mignatti, P., et al., "Tumor Invasion Through the Human Amniotic Membrane; Requirement for a Proteinase Cascade", Cell, 47:487-498 (1986).
Moscatelli, D., "High and Low Affinity Binding Sites for Basic Fibroblast Growth Factor on Cultures Cells: Absence of a Role for Low Affinity Binding in the Stimulation of Plasminogen Activator Production by Bovine Capillary Endothelial Cells", J. Cell. Physiol., 131:123-130 (1987).
Nader, H. B., et al., "Heparin Sequences in the Heparan Sulfate Chains of an Endothelial Cell Proteoglycan", Proc. Natl. Acad. Sci. USA, 84:3565-3569 (1987).
Nakamura, et al., "Purification and Properties of Bacteroides Heparinolyticus Heparinase (Heparin Lyase, EC 4.2.2.7)", J. Clin. Microbiol., 26(5):1070-1071 (1988).
Nugent, M. A., et al., "Kinetics of Basic Fibroblast Growth Factor Binding to Its Receptor and heparan Sulfate Proteoglycan: A Mechanism for Cooperativity", Biochemistry, 31(37):8876-8883 (1992).
Patz, A., "Clinical and Experimental Studies on Retinal Neovascularization", Am. J. Opthalmol., 94:715-743 (1982).
Payza, A. N., et al., "Bacterial Degradation of Heparin", Nature, 177:88-89 (1956).
Bashkin, P., et al., "Basic fibroblast growth factor. . . ," Biochem., 28, No. 4, pp. 1737-1743 (Feb. 21, 1989).
Rapraeger, A. C., et al., "Requirement of heparan Sulfate for bFGF-Mediated Fibroblast Growth and Myoblast Differentiation", Science, 252:1705-1708 (1991).
Rifkin, D. B., et al., "The Involvement of Proteases and Protease Inhibitors in Neovascularization", Acta Biol. Med. Germ., 40:1259-1263 (1981).
Rosengart, T. K., et al., "Heparin Protects Heparin-Binding Growth Factor-I From Proteolytic Inactivation In Vitro ", Biochem. Biophys. Res. Commun., 152:432-440 (1988).
Sasisekharan, R., et al., "Cloning and Expression of Heparinase I Gene from Flavobacterium Heparinum", Proc. Natl. Acad. Sci. USA, 90:3660-3664 (1993).
Salvers, A. A., et al., "Fermentation of Mucin and Plant Polysaccharides by Strains of Bacteroides from the Human Colon", Appl. Environ. Microbiol., 33(2):319-322 (1977).
Schreiber, A. B., et al., "Interaction of Endothelial Cell Growth Factor with Heparin: Characterization by Receptor and Antibody Recognition", Proc. Natl. Acad. Sci. USA, 82:6138-6142 (1985).
Shing, Y., et al., "Heparin Affinity: Purification of a Tumor-Derived Capillary Endothelial Cell Growth Factor", Science, 223:1296-1299.
Taylor, S., et al., "Protamine is an Inhibitor of Angiogenesis", Nature (London), 297:307-312 (1982).
Thornton, S. C., et al., "Human Endothelial Cells: Use of Heparin in Cloning and Long-Term Serial Cultivation", Science, 222:623-625 (1983).
Turnbull, J. E., et al., "Identification of the Basic Fibroblast Growth Factor Binding Sequence in Fibroblast Heparan Sulfate", J. Biol. Chem., 267(15):10337-10341 (1992).
Vlodavsky, I., et al., "Endothelial Cell-derived Basic Fibroblast Growth Factor: Synthesis and Deposition Into Subendothelial Extracellular Matrix", Proc. Natl. Acad. Sci. USA, 84:2292-2296 (1987).
Vlodavsky, I., et al., "Extracellular Matrix-resident Growth Factors and Enzymes: Possible Involvement in Tumor Metastasis and Angiogenesis", Cancer and Metastasis Reviews, 9:203-226 (1990).
Yang, V. C., et al., "Purification and Characterization of heparinase from Flavobacterium Heparinum", J. Biol. Chem., 260:1849-1857 (1987).
Yavon, A., et al., "Cell Surface, heparin-like Molecules Are Required for Binding of Basic Fibroblast Growth Factor to Its High Affinity Receptor", Cell, 64:841-848 (1991).
Zimmermann, J. F., et al., "The Release of heparinase from the Periplasmic Space of Flavobacterium Heparinum by Three-Step Osmotic Shock", Appl. Biochem. Biotech., 30:137-148) (1991).
Cooney Charles L.
Langer Robert S.
Moses Marsha A.
Nugent Matthew A.
Sasisekharan Ramnath
Children's Medical Center Corporation
Massachusetts Institute of Technology
Wityshyn Michael G.
Witz Jean C.
LandOfFree
Method for inhibiting angiogenesis using heparinase does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for inhibiting angiogenesis using heparinase, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for inhibiting angiogenesis using heparinase will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2356631